Drug Trial Radar · NCT01829711
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Last checked: Nov 20, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Apr 29, 2013
Primary completion
May 24, 2017
Study completion Apr 29, 2019
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: \- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results.
Conditions
- Leukemia, Hairy Cell
Interventions
Moxetumomab pasudotoxDrug
IV Bag Protectant for Moxetumomab pasudotoxDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central ReviewTime frame: Full disease assessment (CBC, bone marrow and imaging) at end of treatment (EOT; up to 24 weeks) and post EOT Day 181; CBC monthly for 6 months post EOT, every 3 months post Day 181 for first 2 years and every 6 months thereafter (approximately 6 years)
- Percentage of Participants With Durable CR by Investigator's AssessmentTime frame: Full disease assessment (CBC, bone marrow and imaging) at end of treatment (EOT; up to 24 weeks) and post EOT Day 181; CBC monthly for 6 months post EOT, every 3 months post Day 181 for first 2 years and every 6 months thereafter (approximately 6 years)
Locations
34 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Miami, Florida
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Albuquerque, New Mexico
Research Site
New York, New York
Research Site
Houston, Texas
Research Site
Antwerp, Belgium
Research Site
Ghent, Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Brno, Czechia
Research Site
Caen, France
Research Site
Le Chesnay, France
Research Site
Pessac, France
Research Site
Pierre-Bénite, France
Research Site
Rouen, France
Research Site
Strasbourg, France
Research Site
Berlin, Germany
Research Site
Giessen, Germany
Research Site
Heidelberg, Germany
Research Site
Dublin, Ireland
Research Site
Haifa, Israel
Research Site
Bologna, Italy
Research Site
Genova, Italy
Research Site
Milan, Italy
Research Site
Siena, Italy
Research Site
Bergen, Norway
Research Site
Gdansk, Poland
Research Site
Lodz, Poland
Research Site
Belgrade, Serbia
Research Site
Barcelona, Spain
Research Site
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.